The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
The robotic cardiac procedure between Guyana and India, established a new benchmark in global telesurgery across nearly 20,000 kilometres
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Targeting deadly drug-resistant acinetobacter infections
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
The facility sets a new benchmark in respiratory diagnostics
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
